US20120058986A1 - Di-azetidinyl diamide as monoacylglycerol lipase inhibitors - Google Patents
Di-azetidinyl diamide as monoacylglycerol lipase inhibitors Download PDFInfo
- Publication number
- US20120058986A1 US20120058986A1 US13/224,654 US201113224654A US2012058986A1 US 20120058986 A1 US20120058986 A1 US 20120058986A1 US 201113224654 A US201113224654 A US 201113224654A US 2012058986 A1 US2012058986 A1 US 2012058986A1
- Authority
- US
- United States
- Prior art keywords
- compound
- phenyl
- thiazol
- benzothiophen
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC(C)N1CC2=C(N=CS2)C1=O.CC(C)N1CC2=CC=CC=C2C1=O.[1*]N(C(=O)[Y])C(C)C Chemical compound CC(C)N1CC2=C(N=CS2)C1=O.CC(C)N1CC2=CC=CC=C2C1=O.[1*]N(C(=O)[Y])C(C)C 0.000 description 20
- SINBBFSNGAIJMB-UHFFFAOYSA-N CC(=O)N1CC(N2CC(C)C2)C1 Chemical compound CC(=O)N1CC(N2CC(C)C2)C1 SINBBFSNGAIJMB-UHFFFAOYSA-N 0.000 description 8
- BMITVLGPICLYHP-UHFFFAOYSA-N *.CC.CCC(C)(C)C Chemical compound *.CC.CCC(C)(C)C BMITVLGPICLYHP-UHFFFAOYSA-N 0.000 description 6
- OFKNTJPEMGSCTA-UHFFFAOYSA-N CC(=O)N1CC(N2CC(N3CC4=C(N=CS4)C3=O)C2)C1 Chemical compound CC(=O)N1CC(N2CC(N3CC4=C(N=CS4)C3=O)C2)C1 OFKNTJPEMGSCTA-UHFFFAOYSA-N 0.000 description 3
- NKLONVRWLFYXQS-UHFFFAOYSA-N CC(=O)N1CC(N2CC(N3CC4=CC=CC=C4C3=O)C2)C1 Chemical compound CC(=O)N1CC(N2CC(N3CC4=CC=CC=C4C3=O)C2)C1 NKLONVRWLFYXQS-UHFFFAOYSA-N 0.000 description 3
- KACGPMLBGKNORK-OOAXKADTSA-M C#C[Si](C)(C)C.CC(=O)C1=CC(C#C[Si](C)(C)C)=C(N)C=C1Cl.CC(=O)C1=CC(I)=C(N)C=C1Cl.CC(=O)C1=CC(I)=C(N)C=C1Cl.CC(=O)C1=CC2=C(C=C1Cl)NC=C2.CC(=O)C1=CC=C(N)C(I)=C1Cl.CC(=O)C1=CC=C(N)C=C1Cl.CC(=O)Cl.CCO[Ca]C(=O)O(Cl)ClO.CO.ClI.NC1=CC=C(C(=O)O)C(Cl)=C1.[2H]CF.[Cu]I Chemical compound C#C[Si](C)(C)C.CC(=O)C1=CC(C#C[Si](C)(C)C)=C(N)C=C1Cl.CC(=O)C1=CC(I)=C(N)C=C1Cl.CC(=O)C1=CC(I)=C(N)C=C1Cl.CC(=O)C1=CC2=C(C=C1Cl)NC=C2.CC(=O)C1=CC=C(N)C(I)=C1Cl.CC(=O)C1=CC=C(N)C=C1Cl.CC(=O)Cl.CCO[Ca]C(=O)O(Cl)ClO.CO.ClI.NC1=CC=C(C(=O)O)C(Cl)=C1.[2H]CF.[Cu]I KACGPMLBGKNORK-OOAXKADTSA-M 0.000 description 1
- JPISMJPDNLZHFV-UHFFFAOYSA-N C.C.C.C.C.C#C.C#CC.C#CC#CC.CC#CC.CC(=O)N1CC(N2CC(N3CC4=CC=CC=C4C3=O)C2)C1.CC(C)=O.COC(=O)C1=CC=CC=C1C.NC1CN(P)C1.O=C1C2=C(/C=C\C=C/2)CN1C1CN(P)C1.O=C1C2=C(/C=C\C=C/2)CN1C1CNC1.O=C1C2=CC=CC=C2CN1C1CN(C2CN(P)C2)C1.O=C1C2=CC=CC=C2CN1C1CN(C2CNC2)C1.O=C1CN(P)C1 Chemical compound C.C.C.C.C.C#C.C#CC.C#CC#CC.CC#CC.CC(=O)N1CC(N2CC(N3CC4=CC=CC=C4C3=O)C2)C1.CC(C)=O.COC(=O)C1=CC=CC=C1C.NC1CN(P)C1.O=C1C2=C(/C=C\C=C/2)CN1C1CN(P)C1.O=C1C2=C(/C=C\C=C/2)CN1C1CNC1.O=C1C2=CC=CC=C2CN1C1CN(C2CN(P)C2)C1.O=C1C2=CC=CC=C2CN1C1CN(C2CNC2)C1.O=C1CN(P)C1 JPISMJPDNLZHFV-UHFFFAOYSA-N 0.000 description 1
- KIZFBTQFAGRZRY-UHFFFAOYSA-N C.C.C.C.C.C.C.C.C.C.C1CCOC1.CC(C)(C)OC(=O)N1CC(=O)C1.CC(C)(C)OC(=O)N1CC(N)C1.CC(C)(C)OC(=O)N1CC(N2CC(N3CC4=C(N=CS4)C3=O)C2)C1.CC(C)(C)OC(=O)N1CC(N2CC3=C(N=CS3)C2=O)C1.CC(C)(C)OC(=O)N1CC(NCC2=C(C(=O)O)N=CS2)C1.CC1=C(C(=O)O)N=CS1.COC(=O)C1=C(CBr)SC=N1.COC(=O)C1=C(CNC2CN(C(=O)OC(C)(C)C)C2)SC=N1.O=C(O)C1=CC=C2C(=C1)C=CN2C1=CC=C(C(F)(F)F)C=C1.O=C1C2=C(CN1C1CN(C3CNC3)C1)SC=N2.O=C1C2=C(CN1C1CNC1)SC=N2 Chemical compound C.C.C.C.C.C.C.C.C.C.C1CCOC1.CC(C)(C)OC(=O)N1CC(=O)C1.CC(C)(C)OC(=O)N1CC(N)C1.CC(C)(C)OC(=O)N1CC(N2CC(N3CC4=C(N=CS4)C3=O)C2)C1.CC(C)(C)OC(=O)N1CC(N2CC3=C(N=CS3)C2=O)C1.CC(C)(C)OC(=O)N1CC(NCC2=C(C(=O)O)N=CS2)C1.CC1=C(C(=O)O)N=CS1.COC(=O)C1=C(CBr)SC=N1.COC(=O)C1=C(CNC2CN(C(=O)OC(C)(C)C)C2)SC=N1.O=C(O)C1=CC=C2C(=C1)C=CN2C1=CC=C(C(F)(F)F)C=C1.O=C1C2=C(CN1C1CN(C3CNC3)C1)SC=N2.O=C1C2=C(CN1C1CNC1)SC=N2 KIZFBTQFAGRZRY-UHFFFAOYSA-N 0.000 description 1
- BAUSRNXVMMFYSI-UHFFFAOYSA-N C.C.C.C.C.C.C.C.C.CC(=O)N1CC(N2CC(NC(=O)[Y])C2)C1.CC(=O)[Y].CC(C)=O.NC1CN(P)C1.O=C([Y])NC1CN(C2CN(P)C2)C1.O=C([Y])NC1CN(C2CNC2)C1.O=C([Y])NC1CN(P)C1.O=C([Y])NC1CNC1.O=C1CN(P)C1 Chemical compound C.C.C.C.C.C.C.C.C.CC(=O)N1CC(N2CC(NC(=O)[Y])C2)C1.CC(=O)[Y].CC(C)=O.NC1CN(P)C1.O=C([Y])NC1CN(C2CN(P)C2)C1.O=C([Y])NC1CN(C2CNC2)C1.O=C([Y])NC1CN(P)C1.O=C([Y])NC1CNC1.O=C1CN(P)C1 BAUSRNXVMMFYSI-UHFFFAOYSA-N 0.000 description 1
- CQOSGPOTBMQSKO-UQXQVVHHSA-N C.C.C.C.CC(=O)N1CC(N2CC(N3CC4=C(N=CS4)C3=O)C2)C1.CC(C)=O.CC1=C(C(=O)O)N=CS1.COC(=O)C1=C(CBr)SC=N1.COC(=O)C1=C(CNC2CN(P)C2)SC=N1.NC1CN(P)C1.O=C(O)C1=C(CNC2CN(P)C2)SC=N1.O=C1C2=C(CN1C1CN(C3CN(P)C3)C1)SC=N2.O=C1C2=C(CN1C1CN(C3CNC3)C1)SC=N2.O=C1C2=C(CN1C1CN(P)C1)SC=N2.O=C1C2=C(CN1C1CNC1)SC=N2.O=C1CN(P)C1.[2HH].[2HH].[2HH].[2HH].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H] Chemical compound C.C.C.C.CC(=O)N1CC(N2CC(N3CC4=C(N=CS4)C3=O)C2)C1.CC(C)=O.CC1=C(C(=O)O)N=CS1.COC(=O)C1=C(CBr)SC=N1.COC(=O)C1=C(CNC2CN(P)C2)SC=N1.NC1CN(P)C1.O=C(O)C1=C(CNC2CN(P)C2)SC=N1.O=C1C2=C(CN1C1CN(C3CN(P)C3)C1)SC=N2.O=C1C2=C(CN1C1CN(C3CNC3)C1)SC=N2.O=C1C2=C(CN1C1CN(P)C1)SC=N2.O=C1C2=C(CN1C1CNC1)SC=N2.O=C1CN(P)C1.[2HH].[2HH].[2HH].[2HH].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H].[2H][2H] CQOSGPOTBMQSKO-UQXQVVHHSA-N 0.000 description 1
- RRQPLASXYJFFJQ-UHFFFAOYSA-N C.CC(C)(C)OC(=O)N1CC(=O)C1.CC(C)(C)OC(=O)N1CC(N)C1.CC(C)(C)OC(=O)N1CC(N2CC(N3CC4=C(C=CC=C4)C3=O)C2)C1.CC(C)(C)OC(=O)N1CC(N2CC3=C(C=CC=C3)C2=O)C1.O=C(C1=CC=C(C2=CC=CC=C2)C=C1)N1CC(N2CC(N3CC4=C(C=CC=C4)C3=O)C2)C1.O=C(O)C1=CC=C(C2=CC=CC=C2)C=C1.O=C1C2=C(C=CC=C2)CN1C1CN(C2CNC2)C1.[H]C(=O)C1=CC=CC=C1C(=O)OC Chemical compound C.CC(C)(C)OC(=O)N1CC(=O)C1.CC(C)(C)OC(=O)N1CC(N)C1.CC(C)(C)OC(=O)N1CC(N2CC(N3CC4=C(C=CC=C4)C3=O)C2)C1.CC(C)(C)OC(=O)N1CC(N2CC3=C(C=CC=C3)C2=O)C1.O=C(C1=CC=C(C2=CC=CC=C2)C=C1)N1CC(N2CC(N3CC4=C(C=CC=C4)C3=O)C2)C1.O=C(O)C1=CC=C(C2=CC=CC=C2)C=C1.O=C1C2=C(C=CC=C2)CN1C1CN(C2CNC2)C1.[H]C(=O)C1=CC=CC=C1C(=O)OC RRQPLASXYJFFJQ-UHFFFAOYSA-N 0.000 description 1
- UTULBHXUGYRAOW-UHFFFAOYSA-N C.CC(C)(C)OC(=O)N1CC(=O)C1.CC(C)(C)OC(=O)N1CC(N)C1.CC(C)(C)OC(=O)N1CC(N2CC(NC(=O)C3=CC=CC=C3)C2)C1.CC(C)(C)OC(=O)N1CC(NC(=O)C2=CC=CC=C2)C1.O=C(Cl)C1=CC=CC=C1.O=C(NC1CN(C2CN(C(=O)C3=CC=C(C4=CC=CC=C4)C=C3)C2)C1)C1=CC=CC=C1.O=C(NC1CN(C2CNC2)C1)C1=CC=CC=C1.O=C(O)C1=CC=C(C2=CC=CC=C2)C=C1 Chemical compound C.CC(C)(C)OC(=O)N1CC(=O)C1.CC(C)(C)OC(=O)N1CC(N)C1.CC(C)(C)OC(=O)N1CC(N2CC(NC(=O)C3=CC=CC=C3)C2)C1.CC(C)(C)OC(=O)N1CC(NC(=O)C2=CC=CC=C2)C1.O=C(Cl)C1=CC=CC=C1.O=C(NC1CN(C2CN(C(=O)C3=CC=C(C4=CC=CC=C4)C=C3)C2)C1)C1=CC=CC=C1.O=C(NC1CN(C2CNC2)C1)C1=CC=CC=C1.O=C(O)C1=CC=C(C2=CC=CC=C2)C=C1 UTULBHXUGYRAOW-UHFFFAOYSA-N 0.000 description 1
- PVZVGFIUPJUGHT-UHFFFAOYSA-N C.CC1=CC=C(N2C=CC3=CC(C(=O)N4CC(N5CC(N6CC7=C(N=CS7)C6=O)C5)C4)=CC=C32)C=C1 Chemical compound C.CC1=CC=C(N2C=CC3=CC(C(=O)N4CC(N5CC(N6CC7=C(N=CS7)C6=O)C5)C4)=CC=C32)C=C1 PVZVGFIUPJUGHT-UHFFFAOYSA-N 0.000 description 1
- UPQQHYAYXZXZDB-UHFFFAOYSA-N CC(=O)C1=C(C)C2=C(C=C(Cl)C=C2)S1.CCOC(C)=O.COC(=O)CS.FC1=C(I)C=CC(Cl)=C1.O=C(C1=C(F)C=C(Cl)C=C1)C(F)(F)F Chemical compound CC(=O)C1=C(C)C2=C(C=C(Cl)C=C2)S1.CCOC(C)=O.COC(=O)CS.FC1=C(I)C=CC(Cl)=C1.O=C(C1=C(F)C=C(Cl)C=C1)C(F)(F)F UPQQHYAYXZXZDB-UHFFFAOYSA-N 0.000 description 1
- ANNBVQGYNXFQPF-UHFFFAOYSA-N CC(=O)C1=C(N)C(O)=CC=C1.CC(=O)C1=C(NC(=O)C2=CC=C(F)C=C2)C(O)=CC=C1.CC(=O)C1=C2N=C(C3=CC=C(F)C=C3)OC2=CC=C1.O=C(O)C1=C2N=C(C3=CC=C(F)C=C3)OC2=CC=C1.O=C(O)C1=CC=C(F)C=C1 Chemical compound CC(=O)C1=C(N)C(O)=CC=C1.CC(=O)C1=C(NC(=O)C2=CC=C(F)C=C2)C(O)=CC=C1.CC(=O)C1=C2N=C(C3=CC=C(F)C=C3)OC2=CC=C1.O=C(O)C1=C2N=C(C3=CC=C(F)C=C3)OC2=CC=C1.O=C(O)C1=CC=C(F)C=C1 ANNBVQGYNXFQPF-UHFFFAOYSA-N 0.000 description 1
- LJPYPLCTKHRTNP-RLGPSGOWSA-N CC(=O)C1=CC2=C(C=C1)N(C1=CC=C(F)C=C1)C(C)=N2.CC(=O)C1=CC=C(NC2=CC=C(F)C=C2)C(N)=C1.CC1=NC2=C(C=CC(C(=O)O)=C2)N1C1=CC=C(F)C=C1.CCO.COC(C)(OC)OC.ON[Na].[2H]CF Chemical compound CC(=O)C1=CC2=C(C=C1)N(C1=CC=C(F)C=C1)C(C)=N2.CC(=O)C1=CC=C(NC2=CC=C(F)C=C2)C(N)=C1.CC1=NC2=C(C=CC(C(=O)O)=C2)N1C1=CC=C(F)C=C1.CCO.COC(C)(OC)OC.ON[Na].[2H]CF LJPYPLCTKHRTNP-RLGPSGOWSA-N 0.000 description 1
- QWIYWJFNYRCLOF-RBDUOZFWSA-N CC(=O)C1=CC2=C(C=C1)N(C1=CC=C(F)C=C1)C=N2.CC(=O)C1=CC=C(F)C([N+](=O)[O-])=C1.CC(=O)C1=CC=C(NC2=CC=C(F)C=C2)C(N)=C1.CC(=O)C1=CC=C(NC2=CC=C(F)C=C2)C([N+](=O)[O-])=C1.CCO.CCO.COC(OC)OC.NC1=CC=C(F)C=C1.O=C(O)C1=CC2=C(C=C1)N(C1=CC=C(F)C=C1)C=N2.ON[Na].[2H]CF Chemical compound CC(=O)C1=CC2=C(C=C1)N(C1=CC=C(F)C=C1)C=N2.CC(=O)C1=CC=C(F)C([N+](=O)[O-])=C1.CC(=O)C1=CC=C(NC2=CC=C(F)C=C2)C(N)=C1.CC(=O)C1=CC=C(NC2=CC=C(F)C=C2)C([N+](=O)[O-])=C1.CCO.CCO.COC(OC)OC.NC1=CC=C(F)C=C1.O=C(O)C1=CC2=C(C=C1)N(C1=CC=C(F)C=C1)C=N2.ON[Na].[2H]CF QWIYWJFNYRCLOF-RBDUOZFWSA-N 0.000 description 1
- GFZSRKPMTDJQQR-UHFFFAOYSA-M CC(=O)C1=CC2=C(C=CC(Br)=C2)S1.CC(=O)C1=CC2=C(C=CC(C3=CC=CC=C3)=C2)S1.O.O=C(Cl)C1=C(F)C2=C(C=CC(C3=CC=CC=C3)=C2)S1.O=C(Cl)C1OCl1.O=C(O)C1=C(F)C2=C(C=CC(C3=CC=CC=C3)=C2)S1.O=C(O)C1=CC2=C(C=CC(C3=CC=CC=C3)=C2)S1.O=S(=O)(C1=CC=CC=C1)N(F)S(=O)(=O)C1=CC=CC=C1.OBOC1=CC=CC=C1.[Li]O Chemical compound CC(=O)C1=CC2=C(C=CC(Br)=C2)S1.CC(=O)C1=CC2=C(C=CC(C3=CC=CC=C3)=C2)S1.O.O=C(Cl)C1=C(F)C2=C(C=CC(C3=CC=CC=C3)=C2)S1.O=C(Cl)C1OCl1.O=C(O)C1=C(F)C2=C(C=CC(C3=CC=CC=C3)=C2)S1.O=C(O)C1=CC2=C(C=CC(C3=CC=CC=C3)=C2)S1.O=S(=O)(C1=CC=CC=C1)N(F)S(=O)(=O)C1=CC=CC=C1.OBOC1=CC=CC=C1.[Li]O GFZSRKPMTDJQQR-UHFFFAOYSA-M 0.000 description 1
- BWWLZBAZEFEGNJ-UHFFFAOYSA-M CC(=O)C1=CC=C(N)C(O)=C1.CC(=O)C1=CC=C2N=C(C3=CC=CC=C3)OC2=C1.O=C(Cl)C1=CC=CC=C1.O=C(O)C1=CC=C2N=C(C3=CC=CC=C3)OC2=C1.[Li]O Chemical compound CC(=O)C1=CC=C(N)C(O)=C1.CC(=O)C1=CC=C2N=C(C3=CC=CC=C3)OC2=C1.O=C(Cl)C1=CC=CC=C1.O=C(O)C1=CC=C2N=C(C3=CC=CC=C3)OC2=C1.[Li]O BWWLZBAZEFEGNJ-UHFFFAOYSA-M 0.000 description 1
- MPQIMEYOQQRZSQ-BYPHSZPHSA-N CC(=O)C1=CC=C2=NN(C3=CC(C(F)(F)F)=CC=C3)=CC2=C1.CC(=O)C1=CC=C2C(=C1)C=NN2C1=CC(C)=CC=C1.CC(=O)C1=CC=C2NN=CC2=C1.CC1=CC=CC(N2N=CC3=CC(C(=O)O)=CC=C32)=C1.CC[C@@H]1CCCC[C@H]1CC.FC(F)(F)C1=CC=CC(Br)=C1.O=C(O)C1=CC=C2=NN(C3=CC(C(F)(F)F)=CC=C3)=CC2=C1 Chemical compound CC(=O)C1=CC=C2=NN(C3=CC(C(F)(F)F)=CC=C3)=CC2=C1.CC(=O)C1=CC=C2C(=C1)C=NN2C1=CC(C)=CC=C1.CC(=O)C1=CC=C2NN=CC2=C1.CC1=CC=CC(N2N=CC3=CC(C(=O)O)=CC=C32)=C1.CC[C@@H]1CCCC[C@H]1CC.FC(F)(F)C1=CC=CC(Br)=C1.O=C(O)C1=CC=C2=NN(C3=CC(C(F)(F)F)=CC=C3)=CC2=C1 MPQIMEYOQQRZSQ-BYPHSZPHSA-N 0.000 description 1
- SKZAJFQZWOCHHK-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)C(C1=CC=CC=C1)=NN2C.CC(=O)C1=CC=C2C(=C1)C(I)=NN2C.CN1N=C(C2=CC=CC=C2)C2=CC(C(=O)O)=CC=C21.OBOC1=CC=CC=C1 Chemical compound CC(=O)C1=CC=C2C(=C1)C(C1=CC=CC=C1)=NN2C.CC(=O)C1=CC=C2C(=C1)C(I)=NN2C.CN1N=C(C2=CC=CC=C2)C2=CC(C(=O)O)=CC=C21.OBOC1=CC=CC=C1 SKZAJFQZWOCHHK-UHFFFAOYSA-N 0.000 description 1
- OEYVHCJWTQIXSB-UPLIRYAISA-M CC(=O)C1=CC=C2C(=C1)C=CN2C1=CC(F)=C(F)C=C1.CC(=O)C1=CC=C2NC=CC2=C1.CC[C@@H]1CCCC[C@H]1CC.FC1=C(F)C=C(I)C=C1.O=C(O)C1=CC=C2C(=C1)C=CN2C1=CC(F)=C(F)C=C1.[Li]O Chemical compound CC(=O)C1=CC=C2C(=C1)C=CN2C1=CC(F)=C(F)C=C1.CC(=O)C1=CC=C2NC=CC2=C1.CC[C@@H]1CCCC[C@H]1CC.FC1=C(F)C=C(I)C=C1.O=C(O)C1=CC=C2C(=C1)C=CN2C1=CC(F)=C(F)C=C1.[Li]O OEYVHCJWTQIXSB-UPLIRYAISA-M 0.000 description 1
- KALRTTUZACNPRS-UHFFFAOYSA-M CC(=O)C1=CC=C2C(=C1)C=CN2C1=CC=C(F)C=C1.CC(=O)C1=CC=C2NC=CC2=C1.FC1=CC=C(Br)C=C1.O=C(O)C1=CC=C2C(=C1)C=CN2C1=CC=C(F)C=C1.[Li]O Chemical compound CC(=O)C1=CC=C2C(=C1)C=CN2C1=CC=C(F)C=C1.CC(=O)C1=CC=C2NC=CC2=C1.FC1=CC=C(Br)C=C1.O=C(O)C1=CC=C2C(=C1)C=CN2C1=CC=C(F)C=C1.[Li]O KALRTTUZACNPRS-UHFFFAOYSA-M 0.000 description 1
- QTKMVWWTKORPMR-UHFFFAOYSA-M CC(=O)C1=CC=C2C(=C1)CC=C2C1=CC=C(F)C=C1.CC(=O)C1=CC=C2C(C3=CC=C(F)C=C3)=CN(C(=O)OC(C)(C)C)C2=C1.CC(=O)C1=CC=C2C(I)=CN(C(=O)OC(C)(C)C)C2=C1.O.O=C(O)C1=CC=C2C(=C1)CC=C2C1=CC=C(F)C=C1.OBOC1=CC=C(F)C=C1.[Li]O Chemical compound CC(=O)C1=CC=C2C(=C1)CC=C2C1=CC=C(F)C=C1.CC(=O)C1=CC=C2C(C3=CC=C(F)C=C3)=CN(C(=O)OC(C)(C)C)C2=C1.CC(=O)C1=CC=C2C(I)=CN(C(=O)OC(C)(C)C)C2=C1.O.O=C(O)C1=CC=C2C(=C1)CC=C2C1=CC=C(F)C=C1.OBOC1=CC=C(F)C=C1.[Li]O QTKMVWWTKORPMR-UHFFFAOYSA-M 0.000 description 1
- NWVMYWWMRVNBSQ-UHFFFAOYSA-N CC(=O)C1=CC=C2C(=C1)CC=C2C1=CC=C(F)C=C1.CC(=O)C1=CC=C2C(C3=CC=C(F)C=C3)=CN(C)C2=C1.CI.CN1C=C(C2=CC=C(F)C=C2)C2=CC=C(C(=O)O)C=C21 Chemical compound CC(=O)C1=CC=C2C(=C1)CC=C2C1=CC=C(F)C=C1.CC(=O)C1=CC=C2C(C3=CC=C(F)C=C3)=CN(C)C2=C1.CI.CN1C=C(C2=CC=C(F)C=C2)C2=CC=C(C(=O)O)C=C21 NWVMYWWMRVNBSQ-UHFFFAOYSA-N 0.000 description 1
- JNWFRIDUKYCXBX-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CC(=O)C1.CC(C)(C)OC(=O)N1CC(=O)C1.CC1=CC=C2C=C(C(=O)Cl)SC2=C1.CN(CC1=CC=CC=C1)C1CN(C(=O)OC(C)(C)C)C1.CN(CC1=CC=CC=C1)C1CN(C2CN(C(=O)C3=CC4=C(C=C(C(F)(F)F)C=C4)S3)C2)C1.CN(CC1=CC=CC=C1)C1CN(C2CN(C(=O)OC(C)(C)C)C2)C1.CN(CC1=CC=CC=C1)C1CN(C2CNC2)C1.CN(CC1=CC=CC=C1)C1CNC1.CN(CC1=NC=CS1)C1CN(C2CN(C(=O)C3=CC4=C(C=C(C(F)(F)F)C=C4)S3)C2)C1.CNC1CN(C2CN(C(=O)C3=CC4=C(C=C(C(F)(F)F)C=C4)S3)C2)C1.CNCC1=CC=CC=C1.O=C(O)C1=NC=CS1 Chemical compound CC(C)(C)OC(=O)N1CC(=O)C1.CC(C)(C)OC(=O)N1CC(=O)C1.CC1=CC=C2C=C(C(=O)Cl)SC2=C1.CN(CC1=CC=CC=C1)C1CN(C(=O)OC(C)(C)C)C1.CN(CC1=CC=CC=C1)C1CN(C2CN(C(=O)C3=CC4=C(C=C(C(F)(F)F)C=C4)S3)C2)C1.CN(CC1=CC=CC=C1)C1CN(C2CN(C(=O)OC(C)(C)C)C2)C1.CN(CC1=CC=CC=C1)C1CN(C2CNC2)C1.CN(CC1=CC=CC=C1)C1CNC1.CN(CC1=NC=CS1)C1CN(C2CN(C(=O)C3=CC4=C(C=C(C(F)(F)F)C=C4)S3)C2)C1.CNC1CN(C2CN(C(=O)C3=CC4=C(C=C(C(F)(F)F)C=C4)S3)C2)C1.CNCC1=CC=CC=C1.O=C(O)C1=NC=CS1 JNWFRIDUKYCXBX-UHFFFAOYSA-N 0.000 description 1
- SXYMHEPLKXAKOZ-UHFFFAOYSA-N CC(C)N(Cc1c2nc[s]1)C2=O Chemical compound CC(C)N(Cc1c2nc[s]1)C2=O SXYMHEPLKXAKOZ-UHFFFAOYSA-N 0.000 description 1
- DEPWKHVPXKGJAM-UHFFFAOYSA-N CC1=C(C2=CC=CC=C2)C=CC=C1C(=O)O.CC1=CC(C(=O)O)=CC=C1C1=CC=CC=C1.CC1=CC(C2=CC=C(C(=O)O)C=C2C)=CC=C1.O=C(O)C1=CC(C2=CC=CC=C2)=CC=C1Cl.O=C(O)C1=CC(C2=CC=CC=C2)=CC=C1F.O=C(O)C1=CC(F)=CC(C2=CC=CC=C2)=C1.O=C(O)C1=CC=C(C2=CC=CC=C2)C=C1Cl.O=C(O)C1=CC=C(C2=CC=CC=C2)C=C1F.O=C(O)C1=CC=CC(C2=CC=CC(F)=C2)=C1.O=C(O)C1=CC=CC(C2=CC=CC=C2)=C1F Chemical compound CC1=C(C2=CC=CC=C2)C=CC=C1C(=O)O.CC1=CC(C(=O)O)=CC=C1C1=CC=CC=C1.CC1=CC(C2=CC=C(C(=O)O)C=C2C)=CC=C1.O=C(O)C1=CC(C2=CC=CC=C2)=CC=C1Cl.O=C(O)C1=CC(C2=CC=CC=C2)=CC=C1F.O=C(O)C1=CC(F)=CC(C2=CC=CC=C2)=C1.O=C(O)C1=CC=C(C2=CC=CC=C2)C=C1Cl.O=C(O)C1=CC=C(C2=CC=CC=C2)C=C1F.O=C(O)C1=CC=CC(C2=CC=CC(F)=C2)=C1.O=C(O)C1=CC=CC(C2=CC=CC=C2)=C1F DEPWKHVPXKGJAM-UHFFFAOYSA-N 0.000 description 1
- TYUNUDSEIVRXLF-UHFFFAOYSA-N CC1=CC(Br)=CC=C1C(=O)O.CC1=CC(C2=CC=CC=C2)=CC=C1C(=O)O.OB(O)C1=CC=CC=C1 Chemical compound CC1=CC(Br)=CC=C1C(=O)O.CC1=CC(C2=CC=CC=C2)=CC=C1C(=O)O.OB(O)C1=CC=CC=C1 TYUNUDSEIVRXLF-UHFFFAOYSA-N 0.000 description 1
- JFNRAJNBLMZHKS-UHFFFAOYSA-N CC1=CC(C2=CC(C(=O)O)=CC=C2)=CC=C1.CC1=CC=C(C2=CC(C(=O)O)=CC=C2)C=C1.O=C(O)C1=CC(C2=CC=CC=C2)=CC(C(F)(F)F)=C1.O=C(O)C1=CC=CC(C2=CC=C(F)C=C2F)=C1.O=C(O)C1=CC=CC(C2=CC=CC=C2C(F)(F)F)=C1 Chemical compound CC1=CC(C2=CC(C(=O)O)=CC=C2)=CC=C1.CC1=CC=C(C2=CC(C(=O)O)=CC=C2)C=C1.O=C(O)C1=CC(C2=CC=CC=C2)=CC(C(F)(F)F)=C1.O=C(O)C1=CC=CC(C2=CC=C(F)C=C2F)=C1.O=C(O)C1=CC=CC(C2=CC=CC=C2C(F)(F)F)=C1 JFNRAJNBLMZHKS-UHFFFAOYSA-N 0.000 description 1
- WUNBYWOIKFOZHJ-UHFFFAOYSA-N CC1=CC=C2C=C(C(=O)Cl)SC2=C1.CC1=CC=C2C=C(C(=O)O)SC2=C1.O=C(C1=CC2=C(C=C(C(F)(F)F)C=C2)S1)N1CC(N2CC(N3CC4=C(/C=C\C=C/4)C3=O)C2)C1.O=C1C2=C(C=CC=C2)CN1C1CN(C2CNC2)C1 Chemical compound CC1=CC=C2C=C(C(=O)Cl)SC2=C1.CC1=CC=C2C=C(C(=O)O)SC2=C1.O=C(C1=CC2=C(C=C(C(F)(F)F)C=C2)S1)N1CC(N2CC(N3CC4=C(/C=C\C=C/4)C3=O)C2)C1.O=C1C2=C(C=CC=C2)CN1C1CN(C2CNC2)C1 WUNBYWOIKFOZHJ-UHFFFAOYSA-N 0.000 description 1
- UTNLSIOPPGDFJA-UHFFFAOYSA-N CC1=NC2=CC(C(=O)O)=CC=C2N1C1=CC=C(C(F)(F)F)C=C1.CC1=NC2=CC(C(=O)O)=CC=C2N1C1=CC=C(F)C(F)=C1.CC1=NC2=CC(C(=O)O)=CC=C2N1C1=CC=CC=C1 Chemical compound CC1=NC2=CC(C(=O)O)=CC=C2N1C1=CC=C(C(F)(F)F)C=C1.CC1=NC2=CC(C(=O)O)=CC=C2N1C1=CC=C(F)C(F)=C1.CC1=NC2=CC(C(=O)O)=CC=C2N1C1=CC=CC=C1 UTNLSIOPPGDFJA-UHFFFAOYSA-N 0.000 description 1
- VLNUTKMHYLQCQB-UHFFFAOYSA-N CCC(=O)C(C)(C)C Chemical compound CCC(=O)C(C)(C)C VLNUTKMHYLQCQB-UHFFFAOYSA-N 0.000 description 1
- JQUDAOPPAUAYCI-UHFFFAOYSA-N CN1C=C(C2=CC(C(F)(F)F)=CC=C2)C2=CC=C(C(=O)O)C=C21.CN1C=C(C2=CC=C(C(F)(F)F)C=C2)C2=CC=C(C(=O)O)C=C21 Chemical compound CN1C=C(C2=CC(C(F)(F)F)=CC=C2)C2=CC=C(C(=O)O)C=C21.CN1C=C(C2=CC=C(C(F)(F)F)C=C2)C2=CC=C(C(=O)O)C=C21 JQUDAOPPAUAYCI-UHFFFAOYSA-N 0.000 description 1
- YZZDTLQJTWAEGA-UHFFFAOYSA-N CN1C=C(C2=CC(F)=CC=C2)C2=CC=C(C(=O)O)C=C21 Chemical compound CN1C=C(C2=CC(F)=CC=C2)C2=CC=C(C(=O)O)C=C21 YZZDTLQJTWAEGA-UHFFFAOYSA-N 0.000 description 1
- YKRHPEMXZPXXBZ-UHFFFAOYSA-N CN1N=C(C2=CC(F)=CC=C2)C2=CC(C(=O)O)=CC=C21.CN1N=C(C2=CC=C(F)C=C2)C2=CC(C(=O)O)=CC=C21 Chemical compound CN1N=C(C2=CC(F)=CC=C2)C2=CC(C(=O)O)=CC=C21.CN1N=C(C2=CC=C(F)C=C2)C2=CC(C(=O)O)=CC=C21 YKRHPEMXZPXXBZ-UHFFFAOYSA-N 0.000 description 1
- LCJRDADXTNVKPZ-UHFFFAOYSA-N FC1=C2NC=CC2=CC(Br)=C1.O=C(O)C1=CC(F)=C2NC=CC2=C1 Chemical compound FC1=C2NC=CC2=CC(Br)=C1.O=C(O)C1=CC(F)=C2NC=CC2=C1 LCJRDADXTNVKPZ-UHFFFAOYSA-N 0.000 description 1
- IROVMAGXKDQLRL-UHFFFAOYSA-N O=C(C1=CC=C2C=C(Br)C=CC2=C1)N1CC(N2CC(N3CC4=C(C=CC=C4)C3=O)C2)C1.O=C(C1=CC=C2C=C(C3=CC=CC=C3)C=CC2=C1)N1CC(N2CC(N3CC4=C(C=CC=C4)C3=O)C2)C1.OB(O)C1=CC=CC=C1 Chemical compound O=C(C1=CC=C2C=C(Br)C=CC2=C1)N1CC(N2CC(N3CC4=C(C=CC=C4)C3=O)C2)C1.O=C(C1=CC=C2C=C(C3=CC=CC=C3)C=CC2=C1)N1CC(N2CC(N3CC4=C(C=CC=C4)C3=O)C2)C1.OB(O)C1=CC=CC=C1 IROVMAGXKDQLRL-UHFFFAOYSA-N 0.000 description 1
- MTUNCFOTPUZNJN-UHFFFAOYSA-N O=C(Cl)C1=C(F)C2=C(C=C(C(F)(F)F)C=C2)S1.O=C(O)C1=C(F)C2=C(C=C(C(F)(F)F)C=C2)S1.O=C(O)C1=CC2=C(C=C(C(F)(F)F)C=C2)S1.O=S(=O)(C1=CC=CC=C1)N(F)S(=O)(=O)C1=CC=CC=C1 Chemical compound O=C(Cl)C1=C(F)C2=C(C=C(C(F)(F)F)C=C2)S1.O=C(O)C1=C(F)C2=C(C=C(C(F)(F)F)C=C2)S1.O=C(O)C1=CC2=C(C=C(C(F)(F)F)C=C2)S1.O=S(=O)(C1=CC=CC=C1)N(F)S(=O)(=O)C1=CC=CC=C1 MTUNCFOTPUZNJN-UHFFFAOYSA-N 0.000 description 1
- RDYBKFTXGXXDAI-UHFFFAOYSA-N O=C(O)C1=C2N=C(C3=C(Cl)C=CC=C3)OC2=CC=C1.O=C(O)C1=C2N=C(C3=C(F)C=CC=C3)OC2=CC=C1.O=C(O)C1=C2N=C(C3=CC(Cl)=CC=C3)OC2=CC=C1.O=C(O)C1=C2N=C(C3=CC=C(Cl)C=C3)OC2=CC=C1.O=C(O)C1=C2N=C(C3=CC=CC=C3)OC2=CC=C1.O=C(O)C1=C2N=C(C3=CN=CC=C3)OC2=CC=C1.O=C(O)C1=C2OC(C3=CC(Cl)=CC=C3)=NC2=CC=C1.O=C(O)C1=C2OC(C3=CC(F)=CC=C3)=NC2=CC=C1.O=C(O)C1=C2OC(C3=CC=C(Cl)C=C3)=NC2=CC=C1.O=C(O)C1=C2OC(C3=CC=C(F)C=C3)=NC2=CC=C1 Chemical compound O=C(O)C1=C2N=C(C3=C(Cl)C=CC=C3)OC2=CC=C1.O=C(O)C1=C2N=C(C3=C(F)C=CC=C3)OC2=CC=C1.O=C(O)C1=C2N=C(C3=CC(Cl)=CC=C3)OC2=CC=C1.O=C(O)C1=C2N=C(C3=CC=C(Cl)C=C3)OC2=CC=C1.O=C(O)C1=C2N=C(C3=CC=CC=C3)OC2=CC=C1.O=C(O)C1=C2N=C(C3=CN=CC=C3)OC2=CC=C1.O=C(O)C1=C2OC(C3=CC(Cl)=CC=C3)=NC2=CC=C1.O=C(O)C1=C2OC(C3=CC(F)=CC=C3)=NC2=CC=C1.O=C(O)C1=C2OC(C3=CC=C(Cl)C=C3)=NC2=CC=C1.O=C(O)C1=C2OC(C3=CC=C(F)C=C3)=NC2=CC=C1 RDYBKFTXGXXDAI-UHFFFAOYSA-N 0.000 description 1
- RZZURKQUMZPYIZ-UHFFFAOYSA-N O=C(O)C1=C2OC(C3=CC=CC=C3)=NC2=CC=C1 Chemical compound O=C(O)C1=C2OC(C3=CC=CC=C3)=NC2=CC=C1 RZZURKQUMZPYIZ-UHFFFAOYSA-N 0.000 description 1
- NPGNBUGNQXRXQW-UHFFFAOYSA-N O=C(O)C1=CC=C2C(=C1)C=CN2C1=CC=C(C(F)(F)F)C=C1 Chemical compound O=C(O)C1=CC=C2C(=C1)C=CN2C1=CC=C(C(F)(F)F)C=C1 NPGNBUGNQXRXQW-UHFFFAOYSA-N 0.000 description 1
- PCCLCEIRYPYJAL-UHFFFAOYSA-N O=C(O)C1=CC=C2C(=C1)CC=C2C1=CC(F)=CC=C1.O=C(O)C1=CC=C2C(=C1)CC=C2C1=CC=CC=C1 Chemical compound O=C(O)C1=CC=C2C(=C1)CC=C2C1=CC(F)=CC=C1.O=C(O)C1=CC=C2C(=C1)CC=C2C1=CC=CC=C1 PCCLCEIRYPYJAL-UHFFFAOYSA-N 0.000 description 1
- OCBFMFATCNVPPA-UHFFFAOYSA-N O=C(O)C1=CC=C2C(=C1)N=CN2C1=CC=C(C(F)(F)F)C=C1.O=C(O)C1=CC=C2C(=C1)N=CN2C1=CC=C(F)C(F)=C1.O=C(O)C1=CC=C2C(=C1)N=CN2C1=CC=CC=C1 Chemical compound O=C(O)C1=CC=C2C(=C1)N=CN2C1=CC=C(C(F)(F)F)C=C1.O=C(O)C1=CC=C2C(=C1)N=CN2C1=CC=C(F)C(F)=C1.O=C(O)C1=CC=C2C(=C1)N=CN2C1=CC=CC=C1 OCBFMFATCNVPPA-UHFFFAOYSA-N 0.000 description 1
- SDABFMNPBRYKGJ-UHFFFAOYSA-N O=C(O)C1=CC=C2C(=C1)NC=C2C1=CC=C(C(F)(F)F)C=C1 Chemical compound O=C(O)C1=CC=C2C(=C1)NC=C2C1=CC=C(C(F)(F)F)C=C1 SDABFMNPBRYKGJ-UHFFFAOYSA-N 0.000 description 1
- JUCGZMXWJVYBFD-UHFFFAOYSA-N O=C(c(cc1cc2)ccc1[n]2-c1ccc(C(F)(F)F)cc1)N(C1)CC1N(C1)CC1N(Cc1c2nc[s]1)C2=O Chemical compound O=C(c(cc1cc2)ccc1[n]2-c1ccc(C(F)(F)F)cc1)N(C1)CC1N(C1)CC1N(Cc1c2nc[s]1)C2=O JUCGZMXWJVYBFD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/224,654 US20120058986A1 (en) | 2010-09-03 | 2011-09-02 | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
US13/798,699 US8759533B2 (en) | 2010-09-03 | 2013-03-13 | Di-azetidinyl diamide as monoacylglcerol lipase inhibitors |
US13/798,770 US8759333B2 (en) | 2010-09-03 | 2013-03-13 | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37976410P | 2010-09-03 | 2010-09-03 | |
US13/224,654 US20120058986A1 (en) | 2010-09-03 | 2011-09-02 | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/798,770 Division US8759333B2 (en) | 2010-09-03 | 2013-03-13 | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
US13/798,699 Division US8759533B2 (en) | 2010-09-03 | 2013-03-13 | Di-azetidinyl diamide as monoacylglcerol lipase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120058986A1 true US20120058986A1 (en) | 2012-03-08 |
Family
ID=44645814
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/224,654 Abandoned US20120058986A1 (en) | 2010-09-03 | 2011-09-02 | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
US13/798,699 Active US8759533B2 (en) | 2010-09-03 | 2013-03-13 | Di-azetidinyl diamide as monoacylglcerol lipase inhibitors |
US13/798,770 Active US8759333B2 (en) | 2010-09-03 | 2013-03-13 | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/798,699 Active US8759533B2 (en) | 2010-09-03 | 2013-03-13 | Di-azetidinyl diamide as monoacylglcerol lipase inhibitors |
US13/798,770 Active US8759333B2 (en) | 2010-09-03 | 2013-03-13 | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
Country Status (12)
Country | Link |
---|---|
US (3) | US20120058986A1 (fr) |
EP (1) | EP2611774B1 (fr) |
JP (1) | JP2013536852A (fr) |
KR (1) | KR20130101040A (fr) |
CN (1) | CN103068798A (fr) |
AR (1) | AR082891A1 (fr) |
AU (1) | AU2011296068B2 (fr) |
BR (1) | BR112013005141A2 (fr) |
CA (1) | CA2809991A1 (fr) |
RU (1) | RU2013114771A (fr) |
TW (1) | TW201305132A (fr) |
WO (1) | WO2012030907A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8759333B2 (en) * | 2010-09-03 | 2014-06-24 | Janssen Pharmaceutica Nv | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
WO2016046130A1 (fr) * | 2014-09-22 | 2016-03-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques destinés au traitement de la fibrose |
EP3279191A4 (fr) * | 2015-03-30 | 2018-10-17 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
US10323026B2 (en) | 2016-03-31 | 2019-06-18 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US11274101B2 (en) | 2017-09-29 | 2022-03-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
EP3087067B1 (fr) | 2013-12-26 | 2018-10-24 | Takeda Pharmaceutical Company Limited | Composés 4-(pipérazin-1-yl)-pyrrolidin-2-one comme inhibiteurs de la monoacylglycérol lipase (magl) |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
WO2016049565A1 (fr) * | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions et procédés pour inhiber la ras |
US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
WO2016049524A1 (fr) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Inhibiteurs de protéines mutantes kras g12c |
TW201702232A (zh) | 2015-04-10 | 2017-01-16 | 亞瑞克西斯製藥公司 | 經取代之喹唑啉化合物及其使用方法 |
US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058807A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058768A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
WO2017058915A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines mutantes kras g12c |
EP3356339A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines mutantes kras g12c |
US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017070256A2 (fr) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Méthode de criblage d'inhibiteurs de ras |
JP7015059B2 (ja) | 2015-11-16 | 2022-02-15 | アラクセス ファーマ エルエルシー | 置換複素環式基を含む2-置換キナゾリン化合物およびその使用方法 |
WO2017100546A1 (fr) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Procédés de préparation de dérivés de quinazoléine |
US10463753B2 (en) | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
WO2017172979A1 (fr) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Composés quinazoline substitués et procédés d'utilisation |
WO2017170830A1 (fr) | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | Composé hétérocyclique |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
EP3519402A1 (fr) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibiteurs de protéines mutantes kras g12c |
CN110312711A (zh) | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | 作为ras抑制剂的杂环化合物及其使用方法 |
WO2018140513A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer |
US11059819B2 (en) | 2017-01-26 | 2021-07-13 | Janssen Biotech, Inc. | Fused hetero-hetero bicyclic compounds and methods of use thereof |
WO2018140514A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer |
EP3573964A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
CA3063440A1 (fr) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Inhibiteurs covalents de kras |
WO2018218071A1 (fr) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Composés et leurs procédés d'utilisation pour le traitement du cancer |
US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6124299A (en) | 1997-02-24 | 2000-09-26 | Zymogenetics, Inc. | Calcitonin mimetics |
AU1089599A (en) | 1997-10-15 | 1999-05-03 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
AU3565999A (en) | 1999-04-16 | 2000-11-02 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
EP1522314B1 (fr) | 2002-06-26 | 2014-03-05 | Ono Pharmaceutical Co., Ltd. | Remèdes pour les maladies provoquées par la contraction ou la dilatation vasculaire |
JP4660199B2 (ja) * | 2002-12-23 | 2011-03-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換1−ピペリジン−4−イル−4−アゼチジン−3−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用 |
EP1702916A1 (fr) | 2005-03-18 | 2006-09-20 | Santhera Pharmaceuticals (Schweiz) GmbH | Inhibiteurs de DPP-IV |
PE20071136A1 (es) | 2005-12-21 | 2007-12-29 | Schering Corp | Derivados de anilina sustituida como antagonistas de la histamina h3 |
TW200813018A (en) * | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
FR2915199B1 (fr) | 2007-04-18 | 2010-01-22 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique. |
FR2915197B1 (fr) * | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
EP2283126A1 (fr) * | 2008-04-25 | 2011-02-16 | Janssen Pharmaceutica, N.V. | Structure cristalline de la monoacylglycérol lipase (mgll) |
EP2180048B1 (fr) | 2008-10-09 | 2014-12-17 | Janssen Pharmaceutica N.V. | Forme cristalline alternative de la monoacylglycérol lipase (MGLL) |
PT2421852E (pt) * | 2009-04-22 | 2014-07-31 | Janssen Pharmaceutica Nv | Amidas de piperazinil azetidinil heteroaromáticas e aromáticas como inibidoras da lipase de monoacilglicerol |
RU2011147200A (ru) | 2009-04-22 | 2013-05-27 | Янссен Фармацевтика Нв | Азетидинилдиамиды в качестве ингибиторов моноациглицерин-липазы |
US8435977B2 (en) | 2009-04-22 | 2013-05-07 | Janssen Pharmaceutica, Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
JP2013536852A (ja) | 2010-09-03 | 2013-09-26 | ヤンセン ファーマシューティカ エヌ.ベー. | モノアシルグリセロールリパーゼ阻害剤としてのジ−アゼチジニルジアミド |
-
2011
- 2011-08-31 JP JP2013527247A patent/JP2013536852A/ja active Pending
- 2011-08-31 AU AU2011296068A patent/AU2011296068B2/en not_active Ceased
- 2011-08-31 BR BR112013005141A patent/BR112013005141A2/pt not_active IP Right Cessation
- 2011-08-31 KR KR1020137007955A patent/KR20130101040A/ko not_active Application Discontinuation
- 2011-08-31 RU RU2013114771/04A patent/RU2013114771A/ru not_active Application Discontinuation
- 2011-08-31 CA CA2809991A patent/CA2809991A1/fr not_active Abandoned
- 2011-08-31 CN CN2011800423208A patent/CN103068798A/zh active Pending
- 2011-08-31 WO PCT/US2011/049885 patent/WO2012030907A1/fr active Application Filing
- 2011-08-31 EP EP11755498.0A patent/EP2611774B1/fr active Active
- 2011-09-02 TW TW100131597A patent/TW201305132A/zh unknown
- 2011-09-02 US US13/224,654 patent/US20120058986A1/en not_active Abandoned
- 2011-09-02 AR ARP110103224A patent/AR082891A1/es not_active Application Discontinuation
-
2013
- 2013-03-13 US US13/798,699 patent/US8759533B2/en active Active
- 2013-03-13 US US13/798,770 patent/US8759333B2/en active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8759333B2 (en) * | 2010-09-03 | 2014-06-24 | Janssen Pharmaceutica Nv | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
US8759533B2 (en) * | 2010-09-03 | 2014-06-24 | Janssen Pharmaceutica Nv | Di-azetidinyl diamide as monoacylglcerol lipase inhibitors |
WO2016046130A1 (fr) * | 2014-09-22 | 2016-03-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques destinés au traitement de la fibrose |
US10076517B2 (en) | 2014-09-22 | 2018-09-18 | Inserm (Institut National De La Santé Et De Ka Recherche Médicale | Methods and pharmaceutical compositions for the treatment of fibrosis |
EP3279191A4 (fr) * | 2015-03-30 | 2018-10-17 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
US10323026B2 (en) | 2016-03-31 | 2019-06-18 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US11274101B2 (en) | 2017-09-29 | 2022-03-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Also Published As
Publication number | Publication date |
---|---|
BR112013005141A2 (pt) | 2016-05-10 |
WO2012030907A1 (fr) | 2012-03-08 |
US8759333B2 (en) | 2014-06-24 |
KR20130101040A (ko) | 2013-09-12 |
JP2013536852A (ja) | 2013-09-26 |
AR082891A1 (es) | 2013-01-16 |
CA2809991A1 (fr) | 2012-03-08 |
US20130196969A1 (en) | 2013-08-01 |
EP2611774A1 (fr) | 2013-07-10 |
RU2013114771A (ru) | 2014-10-10 |
TW201305132A (zh) | 2013-02-01 |
US8759533B2 (en) | 2014-06-24 |
US20130196968A1 (en) | 2013-08-01 |
AU2011296068A1 (en) | 2013-03-14 |
EP2611774B1 (fr) | 2015-03-18 |
CN103068798A (zh) | 2013-04-24 |
AU2011296068B2 (en) | 2015-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8759333B2 (en) | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors | |
US8637498B2 (en) | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors | |
US8575363B2 (en) | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | |
US8729064B2 (en) | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | |
AU2011316970A1 (en) | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors | |
AU2010238746B2 (en) | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | |
US8513423B2 (en) | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors | |
EP2421852A1 (fr) | Pipérazinyl azétidinyl amides hétéroaromatiques et aromatiques en tant qu'inhibiteur de la monoacylglycérol lipase | |
TW201313702A (zh) | 作為單醯基甘油脂酶抑制劑之側氧哌□-四氫吖唉醯胺及側氧二氮呯-四氫吖唉醯胺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: JANSSEN PHARMACEUTICA N.V., BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CONNOLLY, PETER J.;MACIELAG, MARK J.;ZHU, BIN;SIGNING DATES FROM 20110608 TO 20110609;REEL/FRAME:027054/0683 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |